Really?
What is the current market cap? 390M Do you realize that, very conservatively, this is 1/3 where it really should be relative to peer companies with the same sets of metrics, etc. And I'm being very, very conservative.
IFFF the data materializes (FDA approval, partners, etc. etc.), a 2B MC will seem like change compared to where the real valuation of this company may land - we are talking about a potential near-cure for cancer here, via a modern and game-changing immunotherapy platform. This isn't a passing thing or some "next trendy" widget or the next "buzz" - this is the real deal.
I'm not sure what you're expectations are, but you need to realize the big picture that is unfolding before you. And I'm not talking about a single-digit billion MC either.
Unfortunately, there are very smart people watching and they will probably gobble-up ADXS before 2018 for 4B or so, which is nice but I believe short of the potential. Hopefully Dan is looking for more.